Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PCV 20 Clear all
Completed Not applicable Interventional

Individualized Perioperative Open Lung Ventilatory Strategy

NCT02158923
View directory record Official record
Conditions
Moderated-high Risk of Postoperative Pulmonary Complication, Abdominal Surgery Expected More Than Two Hours
Interventions
Alveolar recruitment maneuver, Calculation of optimal PEEP, Postoperative CPAP
Procedure
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eating Phenotypes for Childhood Obesity in the Context of Familial Obesity Risk

NCT02928874
View directory record Official record
Conditions
Obesity
Interventions
% COMPX (low ED vs. high ED preload), EAH (low ED vs. high ED snacks)
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years to 9 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chewing Gum for Weight Loss

NCT00971347
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Extra sugar-free chewing gum sticks, nutrition brochure
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

NCT00294203
View directory record Official record
Conditions
Anemia
Interventions
Epoetin Alfa group, Placebo group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

NCT05158140
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
42
States / cities
North Hollywood, California • Northridge, California • Paramount, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Recruiting Phase 2 Interventional

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

NCT00772928
View directory record Official record
Conditions
Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
23
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 20, 2026, 7:37 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery

NCT00991328
View directory record Official record
Conditions
Post-Operative Delirium, Postoperative Cognitive Dysfunction
Interventions
SctO2 < 60 %.
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Terminated Phase 1 Interventional

Distal Radius Steroid

NCT05655130
View directory record Official record
Conditions
Fractures, Bone, Fractures, Closed, Radius Fracture Distal
Interventions
Dexamethasone, Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 20, 2026, 7:37 AM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Recruiting Phase 2 Interventional

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

NCT05417165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
Seema Bhat
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Not yet recruiting Not applicable Interventional

Prediction and Prevention of Postoperative Mortality and Morbidity

NCT06042413
View directory record Official record
Conditions
Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions
Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care
Other · Behavioral · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

NCT02297230
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT), Capecitabine, Trastuzumab, Paclitaxel
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843
View directory record Official record
Conditions
HIV Infections, Streptococcus Pneumoniae
Interventions
pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Tripler AMC, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Not applicable Interventional

A Study of the Effect of Probiotics on Gastrointestinal Function During Pregnancy

NCT03320226
View directory record Official record
Conditions
Pregnancy Early, Nausea Gravidarum, Vomiting of Pregnancy
Interventions
Probiotic 10 (Nature's Bounty)
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 20, 2026, 7:37 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

NCT06720038
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
45
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
View directory record Official record
Conditions
Chickenpox
Interventions
Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 7:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 20, 2026, 7:37 AM EDT